![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Clears Erchonia’s Low Level Laser for Treating Musculoskeletal Pain
FDA Clears Erchonia’s Low Level Laser for Treating Musculoskeletal Pain
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
The FDA has granted Erchonia 510(k) clearance for its FX-635 laser system for the temporary treatment of musculoskeletal pain caused by physical injury.
The system uses controlled, low-level laser technology and diode arms to precisely target areas of pain in the patient’s lower back. It eliminates the need for opioids and nonsteroidal anti-inflammatory drugs. The system is non-invasiveness and has a shorter recuperation period.
Double-blind and placebo-controlled clinical trials showed a 49 percent average pain reduction after treatment without any other therapies.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct